TipRanks
G Medical Innovations Holdings (GMVDF)
OTHER OTC:GMVDF
US Market
GMVDF
G Medical Innovations Holdings
RESEARCH TOOLSreports

G Medical Innovations Holdings (GMVDF) Ratios

28 Followers

G Medical Innovations Holdings Ratios

GMVDF's free cash flow for Q2 2022 was $―. For the 2022 fiscal year, GMVDF's free cash flow was decreased by $ and operating cash flow was $―. See a summary of the company’s cash flow.
Ratios
TTM
Dec 22Dec 21Dec 20Dec 19
Liquidity Ratios
Current Ratio
 0.22--- ―
Quick Ratio
 0.19--- ―
Cash Ratio
 0.03--- ―
Solvency Ratio
 -2.49--- ―
Operating Cash Flow Ratio
 -2.03--- ―
Short-Term Operating Cash Flow Coverage
 -11.23--- ―
Net Current Asset Value
$ -7.40M$ -7.40M$ -4.78M$ -5.26M$ ―
Leverage Ratios
Debt-to-Assets Ratio
 0.43--- ―
Debt-to-Equity Ratio
 -0.28--- ―
Debt-to-Capital Ratio
 -0.40--- ―
Long-Term Debt-to-Capital Ratio
 >-0.01--- ―
Financial Leverage Ratio
 -0.66--- ―
Debt Service Coverage Ratio
 -1.51--- ―
Interest Coverage Ratio
 -5.42--- ―
Debt to Market Cap
 65.37--- ―
Interest Debt Per Share
 8.56--- ―
Net Debt to EBITDA
 -0.21 -0.21 -0.21 -0.24 ―
Profitability Margins
Gross Profit Margin
17.74%---―
EBIT Margin
-223.17%---―
EBITDA Margin
-195.75%---―
Operating Profit Margin
-500.29%---―
Pretax Profit Margin
-315.43%---―
Net Profit Margin
-557.22%---―
Continuous Operations Profit Margin
-315.79%---―
Net Income Per EBT
176.65%---―
EBT Per EBIT
63.05%---―
Return on Assets (ROA)
-510.45%-510.45%-140.33%-230.02%―
Return on Equity (ROE)
368.04%334.95%244.70%199.05%―
Return on Capital Employed (ROCE)
515.69%515.69%-490.52%501.84%―
Return on Invested Capital (ROIC)
892.01%892.01%-218.01%12929.03%―
Return on Tangible Assets
-510.45%-510.45%-140.33%-230.02%―
Earnings Yield
-34166419.27%-1041.66%-77.82%-49.42%―
Efficiency Ratios
Receivables Turnover
 4.68--- ―
Payables Turnover
 0.78--- ―
Inventory Turnover
 12.45--- ―
Fixed Asset Turnover
 1.67--- ―
Asset Turnover
 0.92--- ―
Working Capital Turnover Ratio
 -1.29--- ―
Cash Conversion Cycle
 -360.03 -360.03 -136.57 -247.14 ―
Days of Sales Outstanding
 77.95 77.95 72.47 95.87 ―
Days of Inventory Outstanding
 29.31 29.31 37.54 7.76 ―
Days of Payables Outstanding
 467.29 467.29 246.58 350.77 ―
Operating Cycle
 107.27 107.27 110.01 103.63 ―
Cash Flow Ratios
Operating Cash Flow Per Share
 -25.63--- ―
Free Cash Flow Per Share
 -28.58--- ―
CapEx Per Share
 2.94--- ―
Free Cash Flow to Operating Cash Flow
 1.11--- ―
Dividend Paid and CapEx Coverage Ratio
 -8.71--- ―
Capital Expenditure Coverage Ratio
 -8.71--- ―
Operating Cash Flow Coverage Ratio
 -8.83--- ―
Operating Cash Flow to Sales Ratio
 -4.18--- ―
Free Cash Flow Yield
-79255.16%-871.26%-63.51%-20.32%―
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 >-0.01--- ―
Price-to-Sales (P/S) Ratio
 <0.01--- ―
Price-to-Book (P/B) Ratio
 >-0.01--- ―
Price-to-Free Cash Flow (P/FCF) Ratio
 >-0.01--- ―
Price-to-Operating Cash Flow Ratio
 >-0.01--- ―
Price-to-Earnings Growth (PEG) Ratio
 >-0.01--- ―
Price-to-Fair Value
 >-0.01--- ―
Enterprise Value Multiple
 -0.21--- ―
Enterprise Value
 1.82M 4.16M 20.77M 27.94M ―
EV to EBITDA
 -0.21 -0.48 -2.38 -2.65 ―
EV to Sales
 0.41 0.94 4.19 5.70 ―
EV to Free Cash Flow
 -0.09 -0.20 -1.72 -5.42 ―
EV to Operating Cash Flow
 -0.10 -0.23 -1.81 -6.01 ―
Tangible Book Value Per Share
 -6.34--- ―
Shareholders’ Equity Per Share
 -10.20--- ―
Tax and Other Ratios
Effective Tax Rate
 >-0.01--- ―
Revenue Per Share
 6.13--- ―
Net Income Per Share
 -34.17--- ―
Tax Burden
 1.77 1.77 1.01 0.99 ―
Interest Burden
 1.41 1.41 1.44 1.06 ―
Research & Development to Revenue
 0.52 0.52 0.34 0.27 ―
SG&A to Revenue
 5.62 5.62 1.94 1.59 ―
Stock-Based Compensation to Revenue
 2.83 2.83 0.13 0.59 ―
Income Quality
 0.74 0.74 0.77 0.37 ―
Currency in USD